Indian Astronaut's Mission Could Revolutionise Space Travel For Diabetics
WHO figures suggest there are an estimated 77 million people above the age of suffering from diabetes (type 2) in India.
Indian astronaut, Group Captain Shubanshu Shukla, who will fly to the International Space Station on May 29, will be conducting a key experiment on diabetes during his flight.
The Axiom-4 space mission of four crew members will conduct research which may pave the way for diabetics to be included in the global astronaut corps. The study will be undertaken in micro-gravity conditions of the International Space Station during the fortnight-long mission.
The experiment is called the "Suite Ride" initiative, and the effort marks a significant milestone in the long-term goal of supporting future astronauts with insulin-dependent diabetes (IDDM), a condition historically deemed disqualifying for spaceflight.
The experiment is part of Axiom Space's multi-tiered approach, which aims to eventually demonstrate that astronauts with IDDM can be safely monitored, treated, and participate in off-planet missions.
One person who will be keenly watching this experiment is India's Science Minister, Dr Jitendra Singh, a well-known diabetologist.
The principal investigator for the study, Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Holdings, Abu Dhabi, confirmed that no astronaut will be injected with insulin, but the crew will wear glucose monitoring equipment on the space flight to see how blood glucose levels fluctuate in the 'stressful environment of space'.
They will be validating blood glucose monitoring, data transmission, as well as insulin viability aboard the International Space Station, he added.
According to a 2024 World Health Organisation estimate, 14% of adults aged 18 years and older were living with diabetes, an increase from 7% in 1990, and about 830 million people worldwide have diabetes.
India is considered the diabetes capital of the world. WHO figures suggest there are an estimated 77 million people above the age of suffering from diabetes (type 2) in India, and nearly 25 million are pre-diabetics, i.e, those at a higher risk of developing diabetes in the future.
Burjeel Holdings PLC, a leading super-speciality healthcare provider in the Middle East and the North African region with headquarters in Abu Dhabi, which is spearheading the project, said, They will do groundbreaking mission-focused work on diabetes management in microgravity, along with Axiom Space.
A pivotal moment in this research was the successful technical demonstration conducted on the Galactic 07 mission of 2024, which confirmed that commercially available insulin pens can deliver medication effectively in microgravity, adhering to International Organisation for Standardisation (ISO) guidelines. The promising results have laid the foundation for the upcoming mission that will take place in space.
The Axiom-4 (Ax-4) mission will utilise Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with insulin-dependent diabetes.
The comprehensive preflight, inflight, and post-flight protocols will employ various testing methods to validate these technologies. The Ax-4 mission also plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth.
Testing the behaviour of CGMs and insulin delivery technologies in microgravity and with circadian rhythm disruption is expected to advance the understanding of how such innovations can improve diabetes monitoring and care in remote or underserved areas on Earth. Experts say this research will lay the groundwork for managing diabetes in isolated locations, such as oil rigs, deserts, or rural regions.
Dr Fityan said, "Space is a proving ground, as this research aims to provide invaluable data that will directly benefit underserved communities and difficult-to-reach areas across the globe."
Dr Lucie Low, Chief Scientist, Axiom Space, said, "This may pave the way for the eventual flight of an astronaut with insulin-dependent diabetes mellitus IDDM. The successful demonstration of glucose monitoring on subjects without diabetes will next open the door to flying astronauts with non-insulin-dependent Type 2 diabetes, looking to prove that people with diabetes can one day thrive in the unique environment of space."
Dr. Low added that "I am personally very excited about our 'Suite Ride' experiment because for Axiom, it means that we are enabling new opportunities for a more diverse crew to fly a future, as well as translating those results back into, hopefully, impacts for diabetic patients here on Earth."
Sign up to read this article FREE!
Exclusive Stories:
Dive into content reserved just for members.
Fewer Ads:
A cleaner, more enjoyable reading experience.
Enhanced Interface:
Tailored just for you.
Join Now – It's Free!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
35 minutes ago
- India Today
Will I ever play again? Rishabh Pant's surgeon recalls rehab process after accident
Rishabh Pant's surgeon, Dr Dinshaw Pardiwala recollected the rehabilitation made by the Indian wicketkeeper as he made a full recovery after being involved in a car accident. Pant was involved in the horrific incident in December 2022 while he was heading to his hometown from Delhi as his car hit a divider, leaving the wicketkeeper in a critical had his right knee dislocated along with many other injuries, which saw him be out of the game for around 16 months. Speaking to the Telegraph, Pardiwala said that Pant was extremely lucky to be alive and not lose the blood flow to his right leg, given the injuries he be in an accident like this, where the car actually overturns and blows up, the risk of death is extremely high," said Pardiwala "When your knee dislocates, and all the ligaments break, there's a high possibility of the nerve or the main blood vessel also being injured. If the blood vessel gets injured, you typically have about four to six hours to restore the blood supply."Otherwise, there's a risk of losing your limb. The fact that his blood vessel wasn't injured despite having a severe high-velocity knee dislocation was extremely lucky," said Pardiwala.'Am I ever going to play again?'Pardiwala said that the first question Pant had when he came to the hospital was,"Am I ever going to be able to play again?"The surgeon said that Pant needed a full reconstruction of the right knee given the extent of the injuries he had a lengthy discussion about the fact that these are grievous injuries – we would need to reconstruct the entire knee. Once we reconstruct the entire knee, we're going to have to then work through a whole process of letting it heal, letting it recover, then get back the basic functions – the range, the strength and the stability," said Pant was making progress after the surgery, Dr. Pardiwala was sceptical of his chances of making a comeback to the field. The surgeon said that he was keeping things straightforward with Pant and to take it one step at a time."Typically, when we reconstruct these patients they are happy just to get back to normal life. If they can walk and do some minimal amount of recreational sports, they're happy. I said: 'We can certainly make sure that he walks again. I'm going to try my best to make sure that we can get him back to playing again.' We didn't really want to offer him too much initially, but we did want to give him hope. So I said: 'We'll break it down into steps.' Step one, of course, has to be the surgery."'When we discussed it just after the surgery, the way I told him is the fact you're alive, the fact that your limbs survived – that's two miracles down. If we get you back to competitive cricket, that's going to be a third miracle. Let's just hope for everything, and then take it a step at a time," said magical return to the fieldadvertisementPant made his return to the cricket field in IPL 2024 and scored 446 runs in 13 matches. This earned him a call-up to India's T20 World Cup 2024 squad, which went on to win the title. Pant also made a fantastic return to the Test arena, where he became India's new vice-captain ahead of the England the first Test, Pant became only the second wicketkeeper to score twin centuries in a single game.- EndsMust Watch
The Hindu
40 minutes ago
- The Hindu
WHO says all Covid-19 origin theories still open, after inconclusive study
All hypotheses on how the Covid-19 pandemic began remain open, the World Health Organization said June 27, 2025, following an inconclusive four-year investigation that was hamstrung by crucial information being withheld. The global catastrophe killed an estimated 20 million people, according to the WHO, while shredding economies, crippling health systems and turning people's lives upside-down. The first cases were detected in Wuhan in China in late 2019, and understanding where the SARS-CoV-2 virus that causes Covid came from is key to preventing future pandemics. However, a lengthy investigation launched by the UN's health agency said that pending further data, the origin of Covid and how it first spread remains elusive. "As things stand, all hypotheses must remain on the table, including zoonotic spillover and lab leak," WHO chief Tedros Adhanom Ghebreyesus told a press conference, referring to the two main hypotheses as to how the pandemic began. Expert investigation An initial WHO-Chinese joint report in March 2021 concluded that the virus most likely jumped from bats to humans via an intermediate animal. It deemed a leak from Wuhan's virology laboratories -- known for their research on coronaviruses -- to be "extremely unlikely". However, that investigation faced harsh criticism for lacking transparency and access, and for not seriously evaluating the lab-leak theory. Tedros launched another investigation, setting up the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), comprising 27 international experts, in July 2021. Their 78-page report was published on Friday. It said the weight of available evidence suggests a spillover from animals -- either directly from bats, or through an intermediate host. However, it could not conclude with certainty where and when this happened, nor whether the Wuhan wet market was where the virus first spilled over into humans. That said, the market "appears to be the location for amplification of infection in humans", leading to widespread transmission. "Evidence for widespread infections or cases in any other countries prior to December 2019 is lacking," it added. While spillover was the best supported theory on the evidence currently available, "until further requests for information are met, or more scientific data becomes available, the origins of SARS-CoV-2 and how it entered the human population will remain inconclusive," SAGO chair Marietjie Venter said at the press conference. Lab leak theories "could not be investigated or excluded", she said, because much of the needed information had not been made available. The experts requested unpublished information from other countries, notably Germany and the United States, but without success, she said. Earlier this week, one SAGO member resigned and three others asked for their names to be removed from the report. Crucial question "Over the past five years, we have learned a lot about Covid-19 but there is one crucial question about the pandemic that we have not yet answered: how it started," Tedros said. "Despite our repeated requests, China hasn't provided hundreds of viral sequences from individuals with Covid-19 early in the pandemic, more detailed information on animals sold at markets in Wuhan, and information on work done and biosafety conditions at laboratories in Wuhan," he said. He said WHO has requested access to intelligence reports by governments around the world on the origins of Covid-19. US President Donald Trump's administration has officially embraced the lab leak theory. Moral imperative Tedros said finding out how Covid-19 started was a moral imperative for those who lost their lives in the pandemic and to prevent further outbreaks. He said the virus was continuing to evolve, take lives and leave people suffering with post-Covid conditions, or so-called long Covid. Tedros said the WHO is appealing to countries with information about the origins of Covid-19 to share information. SAGO said it would continue to evaluate any new, sound scientific evidence and update its findings accordingly.
The Hindu
an hour ago
- The Hindu
Alternative to invasive deep brain stimulation (DBS) new technology in Indian market MRgFUS intervention offers medical intervention for tremors
Dressed in a hospital gown 55-year-old Rohit Kumar (name changed) remembers the ice-cold, sterile, brightly lit Magnetic Resonance Imaging (MRI) room that he walked into early this year at Sir Ganga Ram Hospital, West Delhi, seeking treatment for his essential tremors that he has been struggling with for nearly half a decade now. Essential tremor (ET) is one of the most common neurological disorders affecting around 1% of the general population worldwide. The prevalence increases with age, with approximately 5% of individuals over the age of 60 experiencing it. Essential tremor can present several challenges, primarily due to the rhythmic shaking it causes, which can significantly impact daily life activities. While not life-threatening, the tremors can make simple tasks like writing, eating, and dressing difficult, leading to embarrassment, frustration and social isolation. In advanced stages, it can affect speech and swallowing. Mr. Kumar is among the three patients to have successfully undergone the relatively new Magnetic Resonance-guided Focused Ultrasound (MRgFUS) procedure for his essential tremors at Sir Ganga Ram Hospital, the first private hospital in North India offering the treatment. The relatively new technology for the Indian market is currently available in select centres across the country including – Royal Care Super Speciality Hospital in Coimbatore (first to offer the technology), KIMS Hospitals (Telangana), and All India Institute of Medical Sciences, Delhi (first government hospital). An alternative to more invasive surgical procedures like deep brain stimulation (DBS) MRgFUS intervention is a non-surgical procedure that uses focused ultrasound waves guided by MRI to target brain tissue responsible for tremors in patients with Parkinson's disease or essential tremor. Currently approved for Essential Tremor (ET) and Tremor-Dominant Parkinson's Disease (TD-PD), this technique offers new hope for patients whose symptoms significantly disrupt daily life. This one-time medical intervention costing Rs. 19-23 lakh has on-table procedure duration of 1 to 3 hours, according to doctors at Sir Ganga Ram which started offering the treatment early this year. The procedure allows physicians to monitor the treatment in real-time and adjust parameters for optimal safety and efficacy. In simple terms we can see the tremors subsiding as the ultrasound disrupts the abnormal communication that the brain has been sending to the body affected body organs,'' said Anshu Rohatgi, vice-chairperson, Neurology, Sir Ganga Ram who has been doing these procedure at the health facility here. Speaking about this technique that has been available in America for over half-a-decade now he added that besides the real-time monitoring, the other benefits include -- no incisions, minimal to no anaesthesia to patients, rapid symptom relief, minimal recovery time (1–2 days) and, one-time treatment with no implants or batteries. MRgFUS treatment targets the thalamus, a key relay centre in the brain. Focused ultrasound energy is used to thermally ablate this specific area, leading to a marked reduction—and in many cases, near-complete resolution—of tremors, often within the same session. Explaining how the system works Dr. Rohatgi said that the treatment creates a small, targeted lesion in the brain tissue to interrupt abnormal signals causing the tremors, without the need for any incisions or implants. This translates to significantly fewer side effects and a faster recovery time compared to traditional surgical methods. Speaking about her experience with procedure Mrs. Radha (name changed), a retired schoolteacher, said that the debilitating hand tremors for several years had transformed her from an independent, confidence woman who loved socialising to being withdrawn and embarrassed by her inability to perform simple tasks such as drinking water, eating a sandwich, or writing her name. The suggestion of undergoing Deep Brain Stimulation left me in distress and fear and when I got to know about MRgFUS I did initially consider getting treatment at UK but was disappointed because of the long waiting time. That was when I heard about the technology being available in Delhi,'' she said. Mrs. Radha underwent MRgFUS Thalamotomy at Sir Ganga Ram Hospital and experienced immediate results. 'Her right hand became tremor-free during the procedure itself. The next morning, she joyfully drank water without spilling, ate a sandwich on her own, and wrote her name with a steady hand — big victories that marked a huge leap in reclaiming her life,'' said Dr. Rohatgi. Satnam Chhabra, chairman, Department of Neurosurgery adds, 'This is a highly precise procedure performed by a team of neurologists, neurosurgeons, and neuroradiologists. As this is completely non-invasive, all risks associated with open surgery are effectively avoided.' Insightec is a medical technology company that specialises in MR-guided Focused Ultrasound (MRgFUS) and in a written response to The Hindu, Maurice R. Ferré, M.D., CEO and chairman of the board of Company noted that they are committed to expanding access to focused ultrasound technology in India, where the demand for innovative, incisionless treatment options continues to grow. Our efforts are centered not only on advancing care for patients with essential tremor and Parkinson's disease, but also on exploring new clinical indications for our Exablate technology in the treatment of other neurological conditions. With more than 25,000 patients treated globally, and over 200 in India across three leading centers, we are proud of the excellent clinical outcomes and the growing enthusiasm from both physicians and patients. This is just the beginning, as we remain focused on working closely with our distributor partner to bring this transformative technology to even more patients across India,'' he added.
